Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828821 | 0.79 | ADORA3 (0.51) | CYP1A2MEN1PGRADRB2ADORA3 | |
| SCHEMBL11534048 | 0.77 | CYP1A2 (0.39) | CYP1A2HDAC1HDAC8HDAC6HSP90AA1 | |
| SCHEMBL11719048 | 0.73 | HSP90AA1 (0.36) | CYP1A2HDAC1HDAC8HDAC6HSP90AA1 | |
| SCHEMBL11719045 | 0.73 | HSP90AA1 (0.36) | CYP1A2HDAC1HDAC8HDAC6HSP90AA1 | |
| SCHEMBL11720581 | 0.72 | MEN1 (0.36) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL17849760 | 0.69 | CYP2A6 (0.52) | CYP1A2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL29454745 | 0.68 | NISCH (0.50) | CYP1A2HSP90AA1NISCHADORA3MC3R | |
| SCHEMBL78566 | 0.68 | NISCH (0.50) | CYP1A2HSP90AA1NISCHADORA3MC3R | |
| SCHEMBL29598957 | 0.68 | NISCH (0.50) | CYP1A2HSP90AA1NISCHADORA3MC3R | |
| SCHEMBL11716552 | 0.67 | MEN1 (0.42) | HDAC1HDAC8HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452884-B2 | Methods for inhibiting angiogenesis | FOX CHASE CANCER CENTER (US) | 2008-11-18 | — | — | US | claimed |
| US-7199122-B2 | Methods for inhibiting angiogenesis | FOX CHASE CANCER CENTER (US) | 2007-04-03 | — | — | US | claimed |
| US-20070015765-A1 | Novel methods for inhibiting angiogenesis | THE INSTITUTE FOR CANCER RESEARCH | 2007-01-18 | — | — | US | claimed |
| US-4058611-A | PYRAZINYL, BILHARZIASIS, AMOEBIASIS | RHONE-POULENC INDUSTRIES (FR) | 1977-11-15 | — | — | US | claimed |
| US-20230255961-A1 | Rotomeric Isomers of 4-Alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones | ZPNE GROUP GMBH (CH) | 2023-08-17 | — | — | US | disclosed |
| CN-113694068-A | Rotamers of 4-alkyl-5-heteroaryl-3H-1, 2-dithiole-3-thiones | ST知识产权控股公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2021186244-A1 | ROTOMERIC ISOMERS OF 4-ALKYL-5-HETEROARYL-3H-1,2-DITHIOLE-3-THIONES | ST IP HOLDING AG (CH) | 2021-09-23 | — | — | WO | disclosed |
| EP-3853223-A1 | ROTOMERIC ISOMERS OF 4-ALKYL-5-HETEROARYL-3H-1,2- DITHIOLE-3-THIONES | ST IP Holding AG (CH) | 2021-07-28 | — | — | EP | disclosed |
| CN-113166127-A | Rotamers of 4-alkyl-5-heteroaryl-3H-1, 2-dithiole-3-thiones | ST知识产权控股公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210206751-A1 | Rotomeric Isomers of 4-alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones | SUPPORTIVE THERAPEUTICS AG (CH) | 2021-07-08 | — | — | US | disclosed |
| WO-2020058767-A1 | ROTOMERIC ISOMERS OF 4-ALKYL-5-HETEROARYL-3H-1,2- DITHIOLE-3-THIONES | ST IP HOLDING AG (CH) | 2020-03-26 | — | — | WO | disclosed |
| US-9370504-B2 | Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α | SNU R&DB FOUNDATION (KR) | 2016-06-21 | — | — | US | disclosed |
| WO-2008027013-A2 | COMBINATION OF MTOR ANTAGONIST AND ANGIOGENESIS INHIBITOR FOR THE TREATMENT OF CANCER | NATIONAL CANCER CENTRE (SG) | 2008-03-06 | — | — | WO | disclosed |
| US-4058611-A | PYRAZINYL, BILHARZIASIS, AMOEBIASIS | RHONE-POULENC INDUSTRIES (FR) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015765-A1 | Novel methods for inhibiting angiogenesis | TEK, TXNRD3, FLT4 | CYP1A2 3764/4885HDAC1 1022/4885HDAC8 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.